Patent: 6,719,540
✉ Email this page to a colleague
Summary for Patent: 6,719,540
Title: | C3-cyano epothilone derivatives |
Abstract: | The present invention relates to compounds useful in the treatment of cancer or other proliferative diseases represented by formula I: ##STR1## wherein: Q is selected from the group consisting of ##STR2## M is O, NR.sub.9, or CR.sub.10 R.sub.11 ; X is O or NH; and the R groups are as defined, and therapeutic compositions containing them alone or in combination with other therapeutic agents useful in the treatment of cancer or other proliferative diseases. |
Inventor(s): | Regueiro-Ren; Alicia (Middletown, CT), Kim; Soong-Hoon (Titusville, NJ) |
Assignee: | Bristol-Myers Squibb Company (Princeton, NJ) |
Application Number: | 10/386,072 |
Patent Claims: | see list of patent claims |
Details for Patent 6,719,540
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Clinigen, Inc. | PROLEUKIN | aldesleukin | For Injection | 103293 | 05/05/1992 | ⤷ Try a Trial | 2022-03-12 |
Amgen, Inc. | NEUPOGEN | filgrastim | Injection | 103353 | 02/20/1991 | ⤷ Try a Trial | 2022-03-12 |
Amgen, Inc. | NEUPOGEN | filgrastim | Injection | 103353 | 06/28/2000 | ⤷ Try a Trial | 2022-03-12 |
Partner Therapeutics, Inc. | LEUKINE | sargramostim | For Injection | 103362 | 03/05/1991 | ⤷ Try a Trial | 2022-03-12 |
Partner Therapeutics, Inc. | LEUKINE | sargramostim | Injection | 103362 | 03/05/1991 | ⤷ Try a Trial | 2022-03-12 |
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2022-03-12 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |